Mar 03, 2021 / 05:20PM GMT
Joshua Thomas Jennings - Cowen and Company, LLC, Research Division - MD & Senior Research Analyst
Good afternoon. I'm Josh Jennings from the medical devices team, representing Neil Chatterji, Brian Kennedy and Eric Anderson as well. We're moving through the medical devices track here at the 41st Annual Cowen Health Care Conference, and we're excited to have the Chief Executive Officer of CytoSorbents, Dr. Phil Chan, joining us today.
We're going to -- he's going to run through some introductory slides for investors that are new to story and provide some updates, and then we'll move right into the Q&A.
Phil, I'll hand it right over to you. Thanks so much for being here.
Phillip P. Chan - Cytosorbents Corporation - CEO, President & Director
Yes. Absolutely. And thank you very much, Josh, for the invitation. So I am Dr. Phillip Chan. And before I start, let me please remind viewers our safe harbor statement for forward-looking statements.
CytoSorbents is leading the prevention or treatment of life-threatening inflammation
Cytosorbents Corp at Cowen Healthcare Conference (Virtual) Transcript
Mar 03, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers